Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBD
A Phase 3b, Randomized, Controlled, Multicentre Study With Oral Ferric Maltol (Feraccru) or Intravenous Iron (Ferric Carboxy Maltose; FCM), for the Treatment of Iron Deficiency Anaemia in Subjects With Inflammatory Bowel Disease
Sponsor: Shield Therapeutics
A PHASE3 clinical study on Anemia, Iron-Deficiency and Crohn's Disease, this trial is completed. The trial is conducted by Shield Therapeutics and has accumulated 15 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
15 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 10 earlier versions
-
May 2020 — Dec 2020 [monthly]
Completed PHASE3
-
Mar 2020 — May 2020 [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
Jul 2018 — Mar 2020 [monthly]
Recruiting PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE3
-
Jan 2018 — Jun 2018 [monthly]
Recruiting PHASE3
-
Oct 2017 — Jan 2018 [monthly]
Recruiting PHASE3
-
Aug 2017 — Oct 2017 [monthly]
Recruiting PHASE3
-
May 2017 — Aug 2017 [monthly]
Recruiting PHASE3
-
Feb 2017 — May 2017 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Jan 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shield Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Barcelona, Spain , Beaumont, United States , Bellevue, United States , Berlin, Germany , Bountiful, United States , Budapest, Hungary , Chevy Chase, United States , Clichy, France , Córdoba, Spain , Dothan, United States and 34 more locations